|Articles|December 8, 2022
- Pharmaceutical Executive-12-01-2022
- Volume 42
- Issue 12
Pharmaceutical Executive, December 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive December 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 3 years ago
2023 Pipeline Report: Testing the Limitsabout 3 years ago
Business and Passionabout 3 years ago
Back in Person, Sparks Could Fly at Upcoming J.P. Morgan Conferenceabout 3 years ago
Aligning Trust and Transparency in Brand Messagingabout 3 years ago
Pharma Needs to Look Internally for New Leadershipabout 3 years ago
Seeking Concrete Solutions to Europe’s Supply Problemsabout 3 years ago
Pandemic and Politics Shaped Pharma and FDA in 2022about 3 years ago
Medical Affairs Uptickabout 3 years ago
Virtual Medical Affairs Audits: A Viable AlternativeNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026: Bristol Myers Squibb Focuses on the Next Decade
2
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution
3
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
4
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
5

